Recursion Pharmaceuticals Inc. held its 2025 annual meeting of stockholders on June 18, 2025. During the meeting, stockholders voted on several proposals. The election of Class I directors Zachary Bogue, J.D., Zavain Dar, and Robert Hershberg, M.D. Ph.D. was approved. An advisory resolution to approve executive compensation was also approved. Additionally, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001601830-25-000088), on June 18, 2025, and is solely responsible for the information contained therein.
精彩评论